Evaluation of diabetic patients after three month use of continuous subcutaneous insulin infusion, dispensed by a protocolled form at outpatient reference clinic of Taguatinga Regional Hospital

AUTOR(ES)

Miranda, Leonardo Garcia, Pedrosa, Hermelinda Cordeiro, Falleiros, Roberta Kelly Menezes Maciel, Oliveira, Renata de Moraes, Tolentino, Monica, Casulari, Luiz Augusto

FONTE

Arch. Endocrinol. Metab.

DATA DE PUBLICAÇÃO

2015-02

RESUMO

Objective To evaluate the data of continuous subcutaneous insulin infusion protocol (CSII) for diabetics waived by the Health State Secretariat of Distrito Federal (HSSDF) and therapeutic responses three months after the transfer of multiple daily injections regimen for CSII. Subjects and methods Eighty patients (49 female) took part in this experimental study, mean age and disease duration were 27.9 years and 13 years, respectively; 96% patients had type 1 diabetes mellitus. Results The entire sample (ECO) and 3 subgroups (group 1 – A1c decrease, group 2 – A1c stable, and group 3 – A1c increase), stratified according to a ≥ 0.5% change in A1c, were analyzed. Group 1 involved 64% of the patients. The ECO showed a significant A1c decrease: MDI 8.1 ± 1.4% vs. CSII 7.3 ± 0.9%, p < 0.0001 (0.8% difference pro CSII therapy). Group 1 demonstrated an A1c decrease from 8.7% to 7.3% (1.4% difference). Group 2 mean A1c was 7.1%. Rate of hypoglycemia (< 50 mg/dL) decreased 61% in the ECO and 79% in Group 2. Conclusion This study reinforces the safety and efficacy of CSII with a robust A1c reduction and hypoglycemia. The pioneer care HSSDF ambulatory attests to be achievable the free dispensing by Unified Health System (UHS) following a protocol, and this approach results in less wastage to the patient and represents a rational policy of therapy with CSII for UHS. Arch Endocrinol Metab. 2015;59(1):23-8

Documentos Relacionados

• Reversal of diabetic retinopathy by continuous subcutaneous insulin infusion: a case report.
• Peripheral nerve function in patients with painful diabetic neuropathy treated with continuous subcutaneous insulin infusion.
• Effect of continuous subcutaneous insulin infusion on retinopathy.
• Effect of intravenous insulin infusion on mortality among diabetic patients after myocardial infarction.
• Continuous subcutaneous insulin infusion (CSII) does not prevent progression of proliferative and preproliferative retinopathy.